Search results
Showing 331 to 345 of 1286 results for long term conditions
Berotralstat for preventing recurrent attacks of hereditary angioedema (TA738)
Evidence-based recommendations on berotralstat (Orladeyo) for preventing recurrent attacks of hereditary angioedema in people 12 years and older.
Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment (HTE25)
Early value assessment (EVA) guidance on digital therapy for chronic tic disorders and Tourette syndrome....
View recommendations for HTE25Show all sections
This indicator covers the percentage of patients with a new diagnosis of CKD stage G3a-G5 (on the register, within the preceding 12 months) who had eGFR and ACR (urine albumin to creatinine ratio) measurements recorded within 90 days before or after diagnosis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM216
This indicator covers admission rates due to angina in people with diabetes. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG59
Evidence-based recommendations on pemigatinib (Pemaryze) for relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement in adults.
This indicator covers the percentage of patients with diabetes who have a record of a dietary review by a suitably competent professional in the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM28
Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for HER2-low metastatic or unresectable breast cancer after chemotherapy in adults.
This indicator covers the percentage of patients with a new diagnosis of CKD stage G3a–G5 (on the register, within the preceding 12 months) who had eGFR measured on at least 2 occasions separated by at least 90 days, and the second test within 90 days before the diagnosis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM215.
Kidney conditions: CKD and blood pressure when ACR less than 70 (IND235)
This indicator covers the percentage of patients on the CKD register and with an albumin to creatinine ratio (ACR) of less than 70 mg/mmol, without moderate or severe frailty, in whom the last blood pressure reading (measured in the preceding 12 months) is less than 135/85 mmHg if using ambulatory or home monitoring, or less than 140/90 mmHg if monitored in clinic. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM217
Evidence-based recommendations on olaparib (Lynparza) for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy in adults.
This guideline covers the recognition, diagnosis and early management of suspected sepsis in pregnant or recently pregnant people. It includes recommendations on recognition and early assessment, initial treatment, escalating care, finding and controlling the source of infection, early monitoring, information and support, and training and education.
Etanercept and efalizumab for treating moderate to severe plaque psoriasis (TA103)
Evidence-based recommendations on etanercept (Enbrel) for treating severe psoriasis in adults.
Belzutifan for treating tumours associated with von Hippel-Lindau disease (TA1011)
Evidence-based recommendations on belzutifan (Welireg) for treating tumours associated with von Hippel-Lindau disease in adults.
Evidence-based recommendations on niraparib (Zejula) for maintenance treatment of advanced (FIGO stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer after response to first-line platinum-based chemotherapy in adults.
Evidence-based recommendations on zolbetuximab (Vyloy) with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma in adults.